MedTrace Logo

Observational Study of Golimumab Intravenous Infusion

NCT02390700 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2016-11-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the incidence and management of infusion reactions with Golimumab intravenous infusion.

Conditions

Interventions

BIOLOGICAL

Golimumab Intravenous

This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.

Sponsors & Collaborators

  • Janssen Inc.

    lead INDUSTRY

Principal Investigators

  • Janssen Inc. Clinical Trial · Janssen Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02390700 on ClinicalTrials.gov